Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Liver Diseases × fisogatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 1 Liver Diseases 1 Carcinoma, Hepatocellular 1

Interventions

Sorafenib 2 trifluridine tipiracil drug combination 1 trametinib 1 rubitecan 1 repotrectinib 1 pevonedistat 1 pembrolizumab 1 ozanimod 1 fisogatinib 1 ficlatuzumab 1 belinostat 1 bavituximab 1 Trabectedin 1 Radiotherapy 1 Radiosurgery 1 Oxaliplatin 1 Irinotecan 1 Immunotherapy 1 Dexamethasone 1 Azacitidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02508467 2024-04-12

A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

Blueprint Medicines Corporation

Phase 1 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡